Xeltis: Outstanding 12-month First-in-human Data from Xeltis' aXess Hemodialysis Vascular Conduit Trial Presented at VEITHsymposium 2023

Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, announces outstanding 12-month data from its first-in-human (FIH) aXess vascular conduit trial (NCT04898153). The data was presented yesterday by Prof. Dr. Frans Moll at the 50th Annual VEITHsymposium in New York. At 12 months, 100% secondary patency, 78% [...]